Millennium Pharmaceuticals, Inc., of Cambridge, Mass., received an expanded indication for Velcade (bortezomib) for injection, without dose adjustments, in patients with impaired kidney function, including those needing dialysis.

 

In the United States, Velcade is approved for treating patients with multiple myeloma (MM) who have received at least one prior therapy. Kidney dysfunction is a common complication related to MM, affecting approximately 30% of patients at diagnosis and a much larger percentage throughout the disease’s course.


Continue Reading

 

“The ability to use Velcade without dose adjustments in patients with renal dysfunction differentiates it from other multiple myeloma therapies,” said Paul Richardson, MD, clinical director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute Boston and associate professor of medicine, Harvard Medical School.